Cancer CDK Inhibitor Market 2019-2029 - Pipeline Analysis, By Drug Type (Palbociclib, Ribociclib, and Abemaciclib), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI465321 | Publish Date: August 2023 | No. of Pages: 168

Global Cancer CDK Inhibitor Market Overview

According to the World Health Organization, the global burden of cancer was projected to increase from 10 million new cases in 2000 to 15 million in 2015 and based on this continuous rise it is estimated 9 million deaths and more than 11 million patients in 2030. There are three drugs available in the market under the mane Palbociclib, Ribociclib and Abemaciclib. These drugs are cyclin-dependent kinase (CDK) inhibitor that targets CDK4 and CDK6 cell cycle pathway with potential antineoplastic activity. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6 , as seen in certain types of cancer and causes cell cycle deregulation. However these drugs are side-effects too which include mild elevations in serum aminotransferase during therapy and to an unusual form of liver injury called pseudocirrhosis  caused by shrinkage of tumor metastases in the liver combined with desmoplastic changes and vascular damage that can be severe, progressive and even fatal. Cancer CDK Inhibitor Market accounted for US$ 6.0 billion in 2019 and is estimated to be US$ 16.1 billion by 2029 and is anticipated to register a CAGR of 10.4%.

Impact of Covid-19 pandemic on market

COVID-19 is an incomparable global health emergency that has disturbed almost every industries as ongoing research amplifies the research frame work to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. Product supply chain and transportation has also affected due to lockdowns everywhere.

Global Cancer CDK Inhibitor Market Dynamics

 

Increasing prevalence of cancer patients

The increase in mortality and morbidity rates among patients is one of the driver of this market. For instance, according to WHO, there are approximately 14 million cancer incidence every year and the rates are constantly increasing. Almost 1.9 million new cancer cases are expected to be diagnosed in 2021.

High Unmet Medical needs for patients

Cancer patients are looking forward for some advancement in drugs. Further, a large number of companies are now investing into oncology markets to meet the needs of cancer patients. Such companies are contributing for introduction of new drugs with better functionality into market.

Side effects & Unreliable Efficacy

There are many side effects involved in the treatment of this disease. The most common side effect is neutropenia which is temporary and dose-dependent with the white blood count usually return when dose is interrupted or dose is reduce.

Fluctuation in Reimbursement policy by Government and Slow FDA approval

Drug reimbursement for medical oncology hospital outpatient departments remains at ASP plus 6%, and the drug-packaging threshold increased from USD 95-100; reimbursement for drug administration decreased. These fluctuation in reimbursement policies for cancer therapies is acting as a major restraint for the cancer therapy market.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Cancer CDK Inhibitor Market Segmentation

 

 

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

Source: Prophecy Market Insights

Global Cancer CDK Inhibitor Market is segmented based on drug type, distribution channel, and region.

On the basis of Drug Type, Global Cancer CDK Inhibitor Market is segmented into Palbociclib, Ribociclib and Abemaciclib. Palbociclib is dominating in the drug type segment by the total share of 81.2%. Based on Distribution Channel, the target market is segmented into Hospital Pharmacies, Online Pharmacies and Others. Hospital pharmacies is dominating in this segment by sharing 52.5%.

Regional Insights:

On region Global Cancer CDK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American Cancer CDK Inhibitors Market accounted for a revenue share of 35.2% in 2019 and was valued at USD XX million, and is projected to reach USD XX million by 2029, growing at a CAGR of XX from 2019 to 2029.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

 

Conditions

 

Interventions

Phase

Funder Type

Neoplasms

Lymphoma, Non-Hodgkin

 
  • Drug: PD-0332991

 

Phase 1

Industry

Solid Tumor

Hematologic Malignancy
  • Drug: P1446A-05

 

Phase 1

Industry

Recurrent Plasma Cell Myeloma

 
  • Drug: Bortezomib
  • Drug: Dexamethasone
  • Drug: Dinaciclib
  • Other: Laboratory Biomarker Analysis

 

Phase 1

NIH

Estrogen Receptor Negative

HER2/Neu Negative

Male Breast Carcinoma

 
  • Drug: Dinaciclib
  • Drug: Epirubicin Hydrochloride
  • Other: Laboratory Biomarker Analysis

 

Phase 1

NIH

 

 

 

 

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Drug Type- Palbociclib, Ribociclib and Abemaciclib

By Distribution Channel– Hospital Pharmacies, Online Pharmacies and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

 

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030 For the purpose of this study, has segmented Global Cancer CDK Inhibitor Market report based on drug type, distribution channel, and region.

 

 

Global Cancer CDK Inhibitor Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Cancer CDK Inhibitor Market Key Players

The key players operating in Global Cancer CDK Inhibitor Market includes Pfizer Inc., Novartis AG and Eli Lilly Roche, Sanofi, Astex Pharmaceuticals, Bristol-Myers Squibb, Onconova Therapeutics, Inc, AstraZeneca and Merck. Pfizer’s strategy includes active management of their portfolio, maximizing growth of core product segments, acquisitions to strengthen core areas of  portfolio- such as their recent acquisition of AstraZeneca’s small molecule  anti-infective business- and divestitures to increase focus on its core  strengths.

Global Cancer CDK Inhibitor Market Company Profile

  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
  • Eli Lilly
  • Onconova Therapeutics, Inc
  • Roche
  • Sanofi
  •  Astex Pharmaceuticals
  •  Bristol-Myers Squibb
  • AstraZeneca
  •  Merck

“*” marked represents similar segmentation in other categories in the respective section

Global Cancer CDK Inhibitor Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Cancer CDK Inhibitor Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drug Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Pipeline Analysis
    • Price list Analysis
      • Commercially Available CDK Inhibitors Price Analysis
      • Cost of Approved Cancer CDKs Inhibitor
      • Average Cost of CDKs Inhibitors Currently Under Research
      • Comparison of Cancer CDKs inhibitor to other Cancer Drugs & Therapies
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Cancer CDK Inhibitor Market, By Drug Type, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Palbociclib
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Ribociclib
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Abemaciclib
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Cancer CDK Inhibitor Market, By Distribution Channel, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Cancer CDK Inhibitor Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  9. Company Profiles
  • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • R&D Status & Development Activities
        • Mechanism of Action
        • Molecule Type
        • Indications
        • Route of Administration
        • Funding
        • Business Strategies
  • Novartis AG
  • Eli Lilly
  • Roche
  • Sanofi
  • Astex Pharmaceuticals
  • Bristol-Myers Squibb
  • AstraZeneca
  • Merck
  • Onconova Therapeutics, Inc.
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

Global Cancer CDK Inhibitor Market is segmented based on drug type, distribution channel and region.

Rising patients of cancer and advancement in research and technology are the major factor driving growth of the global market

The North American Cancer CDK Inhibitors Market accounted for a revenue share of 35.2% in 2019 and was valued at US$ 4188.9 million and is projected to reach US$ 9923.0 billion by 2029, growing at a CAGR of 9.0%.from 2019 to 2029.